{
    "clinical_study": {
        "@rank": "156314", 
        "arm_group": [
            {
                "arm_group_label": "Risendronate and Cholecalciferol combination", 
                "arm_group_type": "Experimental", 
                "description": "risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month."
            }, 
            {
                "arm_group_label": "Risedronate", 
                "arm_group_type": "Active Comparator", 
                "description": "risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and the safety of Risedronate,\n      cholecalciferol combination tablet in patients with Osteoporosis"
        }, 
        "brief_title": "Post-menopausal Women Osteoporosis(Phase III)", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": "Postmenopausal Women Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the efficacy and the safety of Monthly Risedronate\n      with cholecalciferol on 25 Hydroxyvitamin D level and bone markers patients with\n      osteoporosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. women osteoporosis\n\n          2. patients with a diagnosis of Postmenopausal over 6 Months if they had a bone mineral\n             density T-score of < -2.5 at the mean lumbar spine (L1-4), femoral neck, or total, or\n             a T-score of < -1.0 with radiologic evidence of at least one vertebral fracture.\n             Menopause was defined as no natural menses for at least 1 year and a serum FSH level\n             > 40 IU/L, with a reported hysterectomy\n\n          3. low levels of 25(OH)D > 9 ng/mL\n\n          4. patients who give written consent of agreement to voluntarily participate in the\n             clinical study\n\n          5. patients who can read and understand written instructions\n\n        Exclusion Criteria:\n\n          1. patients who had contraindications to oral bisphosphonates, such as esophageal\n             strictures\n\n          2. ALT, AST \u2265 2\u00d7UNL and Serum Creatinine \u2265 1.5\u00d7UNL\n\n          3. low levels of 25(OH)D (less than 9 ng/mL).\n\n          4. Previous use of oral bisphosphonates and vitamin D were allowed, but a washout period\n             was needed, depending on the duration of treatment. Two-year washout periods were\n             needed for bisphosphonate users and 3-6-month periods were required for vitamin D\n             users of > 200 IU.\n\n          5. drug administration after diagnosing as alcoholic or psychical disease\n\n          6. patients whom the investigators judge as improper to participate in this clinical\n             trial 7)13.patients who have experience to participate in other clinical trial within\n             30 days prior to study participation"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806792", 
            "org_study_id": "HL_RSNPM_301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Risendronate and Cholecalciferol combination", 
                "intervention_name": "risedronate combine", 
                "intervention_type": "Drug", 
                "other_name": "- Other name : Risenex M(risedronate 150mg and cholecalciferol 30,000 IU combined)"
            }, 
            {
                "arm_group_label": "Risedronate", 
                "intervention_name": "Risedronate", 
                "intervention_type": "Drug", 
                "other_name": "Other name : Actonel(Risedronate 150mg)"
            }, 
            {
                "arm_group_label": "Risendronate and Cholecalciferol combination", 
                "intervention_name": "Placebo(for Risedronate)", 
                "intervention_type": "Drug", 
                "other_name": "once a month"
            }, 
            {
                "arm_group_label": "Risedronate", 
                "intervention_name": "Placebo(for risedronate combine)", 
                "intervention_type": "Drug", 
                "other_name": "once a month"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Risedronic acid", 
                "Etidronic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Osteoporosis", 
        "lastchanged_date": "March 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "156-755"
                }, 
                "name": "Chung-ang university hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "For 4 Months, the Multi Center, Double Blinded, Randomized, Active Controlled, Comparative Clinical Study to Assess the Efficacy and the Safety to Improvement Effect of Vit.D of Risenex Plus M Tablet in Patients With In Post-menopausal Women Osteoporosis", 
        "overall_official": {
            "affiliation": "Chung-Ang University Hospital", 
            "last_name": "Hyoung-Moo Park, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "proportion of patients with 25(OH)D level < 20 ng/mL at 16 weeks.", 
            "safety_issue": "No", 
            "time_frame": "16 weeks form first drug adminstration."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806792"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary end point is :\nproportion of patients with 25(OH)D level < 9 ng/mL at 16 weeks\nchange of 25(OH)D level\nchange of BSAP\nchange of CTX\nchange of Ca\nchange of phosphorous\nchange of PTH\nchange of 8-foot walking test, Sit-To-Stand test", 
            "measure": "proportion of patients with 25(OH)D level < 9 ng/mL at 16 weeks, change of 25(OH)D level and Bone Markers.", 
            "safety_issue": "No", 
            "time_frame": "16 weeks form first drug administration."
        }, 
        "source": "Hanlim Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}